These features of the construct stipulate for BCMA’s high selectivity as a therapeutic target for CAR cell therapy of MM, since the extracellular CRD ensures stable and specific binding with the scFv fragment of a CAR [97,98]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.